Enhanced expression of nuclear factor I/B in oxaliplatin-resistant human cancer cell lines

Eiji Kashiwagi, Hiroto Izumi, Yoshihiro Yasuniwa, Ryoko Baba, Yoshiaki Doi, Akihiko Kidani, Tokuzo Arao, Kazuto Nishio, Seiji Naito, Kimitoshi Kohno

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Oxaliplatin is a third-generation platinum drug that has favorable activity in cisplatin-resistant cells. However, the molecular mechanisms underlying oxaliplatin resistance are not well understood. To investigate the molecular mechanisms involved, resistant cell lines were independently derived from colon cancer (DLD1) and bladder cancer (T24) cells. Oxaliplatin-resistant DLD1 OX1 and DLD1 OX2 cell lines were approximately 16.3-fold and 17.8-fold more resistant to oxaliplatin than the parent cell lines, respectively, and had 1.7- and 2.2-fold higher cross-resistance to cisplatin, respectively. Oxaliplatin-resistant T24 OX2 and T24 OX3 cell lines were approximately 5.0-fold more resistant to oxaliplatin than the parent cell line and had 1.9-fold higher cross-resistance to cisplatin. One hundred and fifty-eight genes commonly upregulated in both DLD1 OX1 and DLD1 OX2 were identified by microarray analysis. These genes were mainly involved in the function of transcriptional regulators (14.6%), metabolic molecules (14.6%), and transporters (9.5%). Of these, nuclear factor I/B (NFIB) was upregulated in all oxaliplatin-resistant cells. Downregulation of NFIB rendered cells sensitive to oxaliplatin, but not to cisplatin. Forced expression of NFIB induced resistance to oxaliplatin, but not to cisplatin. Taken together, these results suggest that NFIB is a novel and specific biomarker for oxaliplatin resistance in human cancers.

Original languageEnglish
Pages (from-to)382-386
Number of pages5
JournalCancer Science
Volume102
Issue number2
DOIs
Publication statusPublished - Feb 1 2011

Fingerprint

oxaliplatin
NFI Transcription Factors
Cell Line
Cisplatin
Neoplasms
Urinary Bladder Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Enhanced expression of nuclear factor I/B in oxaliplatin-resistant human cancer cell lines. / Kashiwagi, Eiji; Izumi, Hiroto; Yasuniwa, Yoshihiro; Baba, Ryoko; Doi, Yoshiaki; Kidani, Akihiko; Arao, Tokuzo; Nishio, Kazuto; Naito, Seiji; Kohno, Kimitoshi.

In: Cancer Science, Vol. 102, No. 2, 01.02.2011, p. 382-386.

Research output: Contribution to journalArticle

Kashiwagi, E, Izumi, H, Yasuniwa, Y, Baba, R, Doi, Y, Kidani, A, Arao, T, Nishio, K, Naito, S & Kohno, K 2011, 'Enhanced expression of nuclear factor I/B in oxaliplatin-resistant human cancer cell lines', Cancer Science, vol. 102, no. 2, pp. 382-386. https://doi.org/10.1111/j.1349-7006.2010.01784.x
Kashiwagi, Eiji ; Izumi, Hiroto ; Yasuniwa, Yoshihiro ; Baba, Ryoko ; Doi, Yoshiaki ; Kidani, Akihiko ; Arao, Tokuzo ; Nishio, Kazuto ; Naito, Seiji ; Kohno, Kimitoshi. / Enhanced expression of nuclear factor I/B in oxaliplatin-resistant human cancer cell lines. In: Cancer Science. 2011 ; Vol. 102, No. 2. pp. 382-386.
@article{ba72df9c8343458398665edcbf40369a,
title = "Enhanced expression of nuclear factor I/B in oxaliplatin-resistant human cancer cell lines",
abstract = "Oxaliplatin is a third-generation platinum drug that has favorable activity in cisplatin-resistant cells. However, the molecular mechanisms underlying oxaliplatin resistance are not well understood. To investigate the molecular mechanisms involved, resistant cell lines were independently derived from colon cancer (DLD1) and bladder cancer (T24) cells. Oxaliplatin-resistant DLD1 OX1 and DLD1 OX2 cell lines were approximately 16.3-fold and 17.8-fold more resistant to oxaliplatin than the parent cell lines, respectively, and had 1.7- and 2.2-fold higher cross-resistance to cisplatin, respectively. Oxaliplatin-resistant T24 OX2 and T24 OX3 cell lines were approximately 5.0-fold more resistant to oxaliplatin than the parent cell line and had 1.9-fold higher cross-resistance to cisplatin. One hundred and fifty-eight genes commonly upregulated in both DLD1 OX1 and DLD1 OX2 were identified by microarray analysis. These genes were mainly involved in the function of transcriptional regulators (14.6{\%}), metabolic molecules (14.6{\%}), and transporters (9.5{\%}). Of these, nuclear factor I/B (NFIB) was upregulated in all oxaliplatin-resistant cells. Downregulation of NFIB rendered cells sensitive to oxaliplatin, but not to cisplatin. Forced expression of NFIB induced resistance to oxaliplatin, but not to cisplatin. Taken together, these results suggest that NFIB is a novel and specific biomarker for oxaliplatin resistance in human cancers.",
author = "Eiji Kashiwagi and Hiroto Izumi and Yoshihiro Yasuniwa and Ryoko Baba and Yoshiaki Doi and Akihiko Kidani and Tokuzo Arao and Kazuto Nishio and Seiji Naito and Kimitoshi Kohno",
year = "2011",
month = "2",
day = "1",
doi = "10.1111/j.1349-7006.2010.01784.x",
language = "English",
volume = "102",
pages = "382--386",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Enhanced expression of nuclear factor I/B in oxaliplatin-resistant human cancer cell lines

AU - Kashiwagi, Eiji

AU - Izumi, Hiroto

AU - Yasuniwa, Yoshihiro

AU - Baba, Ryoko

AU - Doi, Yoshiaki

AU - Kidani, Akihiko

AU - Arao, Tokuzo

AU - Nishio, Kazuto

AU - Naito, Seiji

AU - Kohno, Kimitoshi

PY - 2011/2/1

Y1 - 2011/2/1

N2 - Oxaliplatin is a third-generation platinum drug that has favorable activity in cisplatin-resistant cells. However, the molecular mechanisms underlying oxaliplatin resistance are not well understood. To investigate the molecular mechanisms involved, resistant cell lines were independently derived from colon cancer (DLD1) and bladder cancer (T24) cells. Oxaliplatin-resistant DLD1 OX1 and DLD1 OX2 cell lines were approximately 16.3-fold and 17.8-fold more resistant to oxaliplatin than the parent cell lines, respectively, and had 1.7- and 2.2-fold higher cross-resistance to cisplatin, respectively. Oxaliplatin-resistant T24 OX2 and T24 OX3 cell lines were approximately 5.0-fold more resistant to oxaliplatin than the parent cell line and had 1.9-fold higher cross-resistance to cisplatin. One hundred and fifty-eight genes commonly upregulated in both DLD1 OX1 and DLD1 OX2 were identified by microarray analysis. These genes were mainly involved in the function of transcriptional regulators (14.6%), metabolic molecules (14.6%), and transporters (9.5%). Of these, nuclear factor I/B (NFIB) was upregulated in all oxaliplatin-resistant cells. Downregulation of NFIB rendered cells sensitive to oxaliplatin, but not to cisplatin. Forced expression of NFIB induced resistance to oxaliplatin, but not to cisplatin. Taken together, these results suggest that NFIB is a novel and specific biomarker for oxaliplatin resistance in human cancers.

AB - Oxaliplatin is a third-generation platinum drug that has favorable activity in cisplatin-resistant cells. However, the molecular mechanisms underlying oxaliplatin resistance are not well understood. To investigate the molecular mechanisms involved, resistant cell lines were independently derived from colon cancer (DLD1) and bladder cancer (T24) cells. Oxaliplatin-resistant DLD1 OX1 and DLD1 OX2 cell lines were approximately 16.3-fold and 17.8-fold more resistant to oxaliplatin than the parent cell lines, respectively, and had 1.7- and 2.2-fold higher cross-resistance to cisplatin, respectively. Oxaliplatin-resistant T24 OX2 and T24 OX3 cell lines were approximately 5.0-fold more resistant to oxaliplatin than the parent cell line and had 1.9-fold higher cross-resistance to cisplatin. One hundred and fifty-eight genes commonly upregulated in both DLD1 OX1 and DLD1 OX2 were identified by microarray analysis. These genes were mainly involved in the function of transcriptional regulators (14.6%), metabolic molecules (14.6%), and transporters (9.5%). Of these, nuclear factor I/B (NFIB) was upregulated in all oxaliplatin-resistant cells. Downregulation of NFIB rendered cells sensitive to oxaliplatin, but not to cisplatin. Forced expression of NFIB induced resistance to oxaliplatin, but not to cisplatin. Taken together, these results suggest that NFIB is a novel and specific biomarker for oxaliplatin resistance in human cancers.

UR - http://www.scopus.com/inward/record.url?scp=79952083052&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952083052&partnerID=8YFLogxK

U2 - 10.1111/j.1349-7006.2010.01784.x

DO - 10.1111/j.1349-7006.2010.01784.x

M3 - Article

C2 - 21087353

AN - SCOPUS:79952083052

VL - 102

SP - 382

EP - 386

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 2

ER -